Shots: AbbVie exercised its exclusive right to acquire TeneoOne and its TNB-383B based on an interim analysis of an ongoing P-I study that demonstrated ORR (79%), VGPR (63%), CR (29%) […]readmore
Tags : TNB-383B
Shots: TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and […]readmore